GPCRStructure Therapeutics Inc.

Nasdaq structuretx.com


$ 35.77 $ -0.37 (-1.02 %)    

Monday, 20-May-2024 15:59:28 EDT
QQQ $ 454.82 $ 3.15 (0.7 %)
DIA $ 398.57 $ -1.85 (-0.46 %)
SPY $ 530.36 $ 0.61 (0.12 %)
TLT $ 91.26 $ -0.27 (-0.3 %)
GLD $ 225.37 $ 0.90 (0.4 %)
$ 35.78
$ 36.44
$ 0.00 x 0
$ 0.00 x 0
$ 35.58 - $ 36.87
$ 23.73 - $ 75.02
318,366
na
5B
$ 1.08
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-09-2024 03-31-2024 10-Q
2 03-08-2024 12-31-2023 10-K
3 11-17-2023 09-30-2023 10-Q
4 08-10-2023 06-30-2023 10-Q
5 05-11-2023 03-31-2023 10-Q
6 03-30-2023 12-31-2022 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 jmp-securities-reiterates-market-outperform-on-structure-therapeutics-maintains-91-price-target

JMP Securities analyst Jonathan Wolleben reiterates Structure Therapeutics (NASDAQ:GPCR) with a Market Outperform and mainta...

 structure-therapeutics-q1-eps-019-beats-021-estimate

Structure Therapeutics (NASDAQ:GPCR) reported quarterly losses of $(0.19) per share which beat the analyst consensus estimate o...

 cantor-fitzgerald-reiterates-overweight-on-structure-therapeutics-maintains-65-price-target

Cantor Fitzgerald analyst Prakhar Agrawal reiterates Structure Therapeutics (NASDAQ:GPCR) with a Overweight and maintains $6...

 cantor-fitzgerald-reiterates-overweight-on-structure-therapeutics-maintains-65-price-target

Cantor Fitzgerald analyst Prakhar Agrawal reiterates Structure Therapeutics (NASDAQ:GPCR) with a Overweight and maintains $6...

 cantor-fitzgerald-initiates-coverage-on-structure-therapeutics-with-overweight-rating-announces-price-target-of-65

Cantor Fitzgerald analyst Prakhar Agrawal initiates coverage on Structure Therapeutics (NASDAQ:GPCR) with a Overweight ratin...

 jmp-securities-reiterates-market-outperform-on-structure-therapeutics-maintains-91-price-target

JMP Securities analyst Jonathan Wolleben reiterates Structure Therapeutics (NASDAQ:GPCR) with a Market Outperform and mainta...

 nasdaq-gains-100-points-biomerica-shares-spike-higher

U.S. stocks traded mostly higher toward the end of trading, with the Nasdaq Composite gaining over 100 points on Monday. The D...

 why-lantheus-holdings-shares-are-trading-lower-by-over-22-here-are-other-stocks-moving-in-mondays-mid-day-session

Shares of Lantheus Holdings, Inc. (NASDAQ: LNTH) fell sharply during Monday’s session after the company and POINT Biopharma ann...

 crude-oil-rises-3-us-housing-market-index-increases-in-december

U.S. stocks traded higher midway through trading, with the Dow Jones index gaining around 50 points on Monday. The Dow traded ...

 why-is-novo-nordisks-potential-obesity-drug-rival-structure-therapeutics-stock-tanking-today

Structure Therapeutics Inc (NASDAQ: GPCR) shares are trading lower after the company provided a comprehensive development progr...

 dow-gains-over-50-points-nippon-steel-to-acquire-u-s-steel

U.S. stocks traded higher this morning, with the Dow Jones index gaining around 50 points on Monday. Following the market open...

 structure-therapeutics-provides-comprehensive-gsbr-1290-program-update-including-clinically-meaningful-proof-of-concept-data-from-phase-2a-clinical-study

Structure Therapeutics Inc. (NASDAQ:GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecu...

 jmp-securities-reiterates-market-outperform-on-structure-therapeutics-maintains-91-price-target

JMP Securities analyst Jonathan Wolleben reiterates Structure Therapeutics (NASDAQ:GPCR) with a Market Outperform and mainta...

 jmp-securities-maintains-market-outperform-on-structure-therapeutics-raises-price-target-to-91

JMP Securities analyst Jonathan Wolleben maintains Structure Therapeutics (NASDAQ:GPCR) with a Market Outperform and raises ...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION